Logo image of VIVO.CA

VIVO Cannabis Inc (VIVO.CA) Stock Fundamental Analysis

TSX:VIVO - Toronto Stock Exchange - CA92845J1049 - Common Stock - Currency: CAD

0.025  0 (0%)

Fundamental Rating

1

Overall VIVO gets a fundamental rating of 1 out of 10. We evaluated VIVO against 34 industry peers in the Pharmaceuticals industry. VIVO has a bad profitability rating. Also its financial health evaluation is rather negative. VIVO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VIVO had negative earnings in the past year.
VIVO had a negative operating cash flow in the past year.
VIVO.CA Yearly Net Income VS EBIT VS OCF VS FCFVIVO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -20M -40M -60M

1.2 Ratios

VIVO has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VIVO.CA Yearly ROA, ROE, ROICVIVO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 100 200 300 400

1.3 Margins

The Gross Margin of VIVO (3.71%) is worse than 60.00% of its industry peers.
In the last couple of years the Gross Margin of VIVO has declined.
The Profit Margin and Operating Margin are not available for VIVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.73%
GM growth 5YN/A
VIVO.CA Yearly Profit, Operating, Gross MarginsVIVO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

VIVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VIVO has more shares outstanding
The debt/assets ratio for VIVO is higher compared to a year ago.
VIVO.CA Yearly Shares OutstandingVIVO.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M
VIVO.CA Yearly Total Debt VS Total AssetsVIVO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -6.64, we must say that VIVO is in the distress zone and has some risk of bankruptcy.
VIVO has a Altman-Z score of -6.64. This is in the lower half of the industry: VIVO underperforms 75.56% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that VIVO is not too dependend on debt financing.
VIVO has a Debt to Equity ratio of 0.06. This is in the better half of the industry: VIVO outperforms 64.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -6.64
ROIC/WACCN/A
WACC9.75%
VIVO.CA Yearly LT Debt VS Equity VS FCFVIVO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 2.58 indicates that VIVO has no problem at all paying its short term obligations.
VIVO has a Current ratio of 2.58. This is comparable to the rest of the industry: VIVO outperforms 60.00% of its industry peers.
A Quick Ratio of 1.17 indicates that VIVO should not have too much problems paying its short term obligations.
The Quick ratio of VIVO (1.17) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 1.17
VIVO.CA Yearly Current Assets VS Current LiabilitesVIVO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for VIVO have decreased strongly by -111.94% in the last year.
Looking at the last year, VIVO shows a decrease in Revenue. The Revenue has decreased by -2.18% in the last year.
The Revenue has been growing by 106.85% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-111.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-254.67%
Revenue 1Y (TTM)-2.18%
Revenue growth 3Y36.95%
Revenue growth 5Y106.85%
Sales Q2Q%-0.12%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VIVO.CA Yearly Revenue VS EstimatesVIVO.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 10M 20M 30M
VIVO.CA Yearly EPS VS EstimatesVIVO.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 -0.05 -0.1 -0.15 -0.2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VIVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIVO.CA Price Earnings VS Forward Price EarningsVIVO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIVO.CA Per share dataVIVO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VIVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVO Cannabis Inc

TSX:VIVO (4/4/2023, 7:00:00 PM)

0.025

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)01-06 2022-01-06
Inst Owners0.08%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.27M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.37
P/FCF N/A
P/OCF N/A
P/B 0.25
P/tB 0.25
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.07
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.71%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.73%
GM growth 5YN/A
F-Score2
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.58
Quick Ratio 1.17
Altman-Z -6.64
F-Score2
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)67.34%
Cap/Depr(5y)294.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-111.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-254.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.18%
Revenue growth 3Y36.95%
Revenue growth 5Y106.85%
Sales Q2Q%-0.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.51%
OCF growth 3YN/A
OCF growth 5YN/A